Immunogenicity and Safety Study of Different Formulations of GSK Biologicals' Herpes Zoster Vaccine 1437173A When Administered Twice in Adults Aged 50 Years and Older.
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2017
At a glance
- Drugs GSK 1437173A (Primary) ; AS01B; AS01E
- Indications Herpes zoster
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 16 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Feb 2010 Planned end date changed from 1 Nov 2009 to 1 Jul 2010 as reported by ClinicalTrials.gov.